New combo therapy aims to extend life in aggressive lung cancer
NCT ID NCT04745689
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests whether adding the drug AZD2811 to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer under control after initial treatment. About 31 adults with this advanced cancer will receive the combination as maintenance therapy. The goal is to see if it delays cancer growth and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Grand Rapids, Michigan, 49503, United States
-
Research Site
Bydgoszcz, 85-796, Poland
-
Research Site
Olsztyn, 10-357, Poland
-
Research Site
Poznan, 60-693, Poland
-
Research Site
Cheongju-si, 28644, South Korea
-
Research Site
Jinju, 52727, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Seville, 41071, Spain
-
Research Site
Valencia, 46015, Spain
Conditions
Explore the condition pages connected to this study.